Agomab Therapeutics NV
For the period ended Apr 24, 2026. Filed Apr 24, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Apr 24, 2026 · Filed Apr 24, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · Availability of documents
Availability of documents
In preparation for the general meeting, please consult the documents listed below, which are attached hereto and available on the Company’s website (https://ir.agomab.com/governance/shareholder-meetings).
| 1. | Consolidated financial statements prepared in accordance with International Financial Reporting Standards for the financial year ended December 31, 2025; |
| 2. | The statutory financial statements for the financial year ended December 31, 2025; |
| 3. | The statutory auditor’s report on the statutory financial statements for the financial year ended December 31, 2025; |
| 4. | The report of the Board of Directors on the statutory financial statements for the financial year ended December 31, 2025; |
| 5. | Proxy form; |
| 6. | Voting form. |
Prior to the general meeting, the Company’s holders of securities may also obtain a copy of the aforementioned documentation free of charge at the Company’s registered office (Posthoflei 1, Box 6, 2600 Antwerp (Berchem), Belgium).
Sincerely, on behalf of the Board of Directors
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.